



**National  
Multiple Sclerosis  
Society**

The Honorable Jamie Becker-Finn, Chair and Committee Members  
MN House of Representatives Judiciary Finance and Civil Law Committee  
559 State Office Building  
St. Paul, MN 55155

Dear Representative Becker-Finn and Members:

On behalf of the National Multiple Sclerosis Society, we applaud the intent of HF 17 as it attempts to address and even limit the costs of medications that treat chronic diseases such as multiple sclerosis (MS). We are pleased to share our support for the Prescription Drug Affordability Act Sections 7-14. The resulting prescription drug affordability board established through this legislation could provide the meaningful oversight needed to reform the system to work better.

Multiple sclerosis (MS) is an unpredictable disease of the central nervous system. Currently, there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.

### **Impact of escalating DMT prices**

While the progress, severity, and specific symptoms of MS in any one person cannot yet be predicted, a growing body of evidence indicates that early and ongoing treatment with a disease-modifying therapy (DMT) is the best way to modify the course of the disease, prevent the accumulation of disability and protect the brain.

People with a chronic illness like MS need to know they can afford the life-changing medication they need when they need it.

Nearly three-quarters of MS medications average more than one price increase per year. In 2013, the average price of MS DMTs was around \$60,000; in 2018, the median price of brand DMTs increased to \$80,000; four years later, in 2022, the brand median price was close to \$94,000. Six MS DMTs have increased in price by more than 200% since they came on the market, and nine are now priced at more than \$100,000 per year. We continue to see significant annual price increases for most of these medications.

The current trajectory of DMT costs is unsustainable for the government, taxpayers, and those living with chronic conditions such as MS. In a recent survey of people with MS conducted by our



**National  
Multiple Sclerosis  
Society**

organization, 40% of people with MS shared that they altered or stopped taking their medications due to high cost. They may have stopped treatment, skipped or delayed filling a prescription, skipped or delayed treatment, or didn't take the medication as prescribed to try and make it last longer.

### **Solutions for people with MS**

We believe that HF 17/SF 168 has the potential to help address the high costs of MS medications. Prescription drug affordability boards (PDAB) can provide important oversight needed to protect consumers, including people living with MS.

We appreciate that Prescription Drug Affordability Act sections of HF 17/SF 168 utilize a multi-stakeholder approach in forming the prescription drug affordability council, acknowledging the roles of health plans, employers, clinical researchers, drug manufacturers, patients, and others. The National MS Society believes that no single stakeholder has all the solutions; we can only find the solutions together, and we strongly support the inclusion of patient and healthcare consumer perspectives.

A robust board would have the authority to conduct cost reviews of high-cost prescription drugs. If found to create affordability challenges for the state health care system or patients, the PDAB could set an upper payment limit (UPL) for what is paid in the State of Minnesota for that medication. This would put downward pressure on drug prices throughout the supply chain for all payers and similar classes of drugs.

The National MS Society supports the intent of HF 17/SF 168 to help shed light on complex issues in the prescription drug market and stabilize the price of medications through the UPL established in section 14. HF 17/SF168 increases transparency so that more information and notification about drug pricing is available.

The Society is here to serve as a resource, so we hope you will feel free to contact us if you have any questions about our position. Prescription drugs cannot improve lives if people can't afford to access them.

Sincerely,

Christina Pierson  
Sr. Manager of Advocacy  
National Multiple Sclerosis Society  
Upper Midwest Chapter